ロザイ・ドルフマン病の世界市場レポート 2025年

ロザイ・ドルフマン病の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.3％で、7億1,000万米ドルに成長します。この成長は、分子診断技術の幅広い採用、希少疾患を取り巻く認知度の向上、臨床研究活動の活発化、ヘルスケアサービスの利用可能性の向上、遠隔医療プラットフォームの利用増加、疾患関連遺伝子マーカーの継続的な同定などからもたらされると予想されます。今後の動向として注目されるのは、診断プロセスにおける人工知能の利用、デジタルヘルス技術の拡大、学術機関と業界利害関係者の連携努力、疾患特異的治療プロトコルの作成、ゲノム解析戦略の進展などです。

標的療法に対する需要の高まりがロザイ・ドルフマン病市場の成長を牽引すると予想されます。標的療法は、健康な細胞を温存しながら、腫瘍の発達を促進する特定の遺伝子変異や細胞メカニズムを攻撃するように設計された精密薬です。病気の原因となる細胞を正確に狙い撃ちし、健康な組織へのダメージを最小限に抑えることで、従来の治療法よりも副作用が少なく治療成績の向上につながることから、需要が拡大しています。ロザイ・ドルフマン病の治療において、標的療法は、組織球の異常増殖につながるMAPK/ERKなどの重要な経路をブロックすることによって機能し、より少ない副作用で効果的に病気を管理します。これらの治療は、疾患特異的なメカニズムに焦点を当て、罹患していない組織への害を回避します。例えば、2023年7月、米国遺伝子・細胞治療学会（ASGCT）は、2023年第3四半期にフェーズII段階にある標的遺伝子治療は247件で、第2四半期と比較して5％増加したと報告しました。その結果、標的療法に対する需要の高まりがロザイ・ドルフマン病市場の拡大に寄与しています。

また、免疫関連合併症の増加もロザイ・ドルフマン病市場の成長を支えるものと予想されます。免疫関連合併症は、免疫システムの過剰な活動や機能不全が害をもたらす場合に発生し、多くの場合、感染症、自己免疫疾患、免疫療法に関連しています。この増加は、過剰な免疫反応を引き起こし、炎症や健康な組織への損傷をもたらす可能性のある免疫療法の使用増加によるものです。ロザイ・ドルフマン病は免疫系の異常と関連しており、自己免疫疾患、感染症、免疫療法の副作用による免疫関連の合併症の増加が、発症や増悪の一因になっていると考えられています。この動向は、診断、研究注目、治療開発の拡大を促しています。例えば、2024年11月にVersorgungsatlas.deが報告したところによると、2022年にはドイツの被保険者7,324万1,305人のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％でした。したがって、免疫関連合併症の増加率は、ロザイ・ドルフマン病市場の発展に重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のロザイ・ドルフマン病：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のロザイ・ドルフマン病市場：成長率分析
• 世界のロザイ・ドルフマン病市場の実績：規模と成長、2019～2024年
• 世界のロザイ・ドルフマン病市場の予測：規模と成長、2024～2029年、2034年
• 世界のロザイ・ドルフマン病：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のロザイ・ドルフマン病市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 古典的（結節性）ロザイ・ドルフマン病
• 節外性ロザイ・ドルフマン病
• 世界のロザイ・ドルフマン病市場：処置タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 診断
• 治療
• 世界のロザイ・ドルフマン病市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 舌下
• 鼻腔
• 世界のロザイ・ドルフマン病市場：年齢別、実績と予測、2019～2024年、2024～2029年、2034年
• 子供
• 成人
• 世界のロザイ・ドルフマン病市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 診断機関
• がんセンター
• その他
• 世界のロザイ・ドルフマン病市場：古典的（結節性）ロザイ・ドルフマン病のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 頸部リンパ節転移
• 腋窩リンパ節転移
• 鼠径リンパ節転移
• 縦隔リンパ節転移
• 全身性リンパ節腫脹
• 世界のロザイ・ドルフマン病市場：節外性ロザイ・ドルフマン病のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚または皮下ロザイ・ドルフマン病
• 中枢神経系（CNS）ロザイ・ドルフマン病
• 眼窩または眼球ロザイ・ドルフマン病
• 骨と骨格ロザイ・ドルフマン病
• 鼻または副鼻腔ロザイ・ドルフマン病
• 腎臓ロザイ・ドルフマン病
• 肺ロザイ・ドルフマン病
• 肝臓または脾臓ロザイ・ドルフマン病
• 乳房ロザイ・ドルフマン病

第7章 地域別・国別分析

• 世界のロザイ・ドルフマン病市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のロザイ・ドルフマン病市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ロザイ・ドルフマン病市場：競合情勢
• ロザイ・ドルフマン病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Canon Inc.
• Siemens Healthineers
• GE HealthCare
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Memorial Sloan Kettering Cancer Center
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma
• Mayo Foundation for Medical Education and Research
• Zydus Pharmaceuticals Inc.
• SternMed GmbH
• LGM Pharma
• Niksan Pharmaceutical
• Herbert Irving Cancer Center

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ロザイ・ドルフマン病市場2029年：新たな機会を提供する国
• ロザイ・ドルフマン病市場2029年：新たな機会を提供するセグメント
• ロザイ・ドルフマン病市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Rosai-Dorfman disease is an uncommon, non-cancerous condition marked by an excessive accumulation of a particular immune cell known as histiocytes, primarily within lymphatic tissues. It typically manifests as large, painless swelling of lymph nodes, especially in the cervical region, though other organs and tissues can also be involved. Diagnosis is usually confirmed through biopsy and pathological analysis, and treatment approaches range from watchful waiting to surgical intervention or the use of immunosuppressive medications, depending on the disease's severity and the organs affected.

The primary forms of Rosai-Dorfman disease include classic (nodal) Rosai-Dorfman disease and extranodal Rosai-Dorfman disease. Classic (nodal) Rosai-Dorfman disease mainly affects lymph nodes in the neck, presenting with painless enlargement, and is the most frequently observed type. Treatment encompasses various procedural approaches, such as diagnostic and therapeutic measures, and is delivered via multiple administration routes, including oral, parenteral, sublingual, and nasal. The disease affects both pediatric and adult populations, and the main end-users include hospitals, diagnostic laboratories, oncology centers, and other healthcare providers.

The Rosai-Dorfman disease market research report is one of a series of new reports from The Business Research Company that provides rosai-dorfman disease market statistics, including the rosai-dorfman disease industry global market size, regional shares, competitors with the rosai-dorfman disease market share, detailed rosai-dorfman disease market segments, market trends, opportunities, and any further data you may need to thrive in the rosai-dorfman disease industry. This rosai-dorfman disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rosai-dorfman disease market size has grown strongly in recent years. It will grow from $0.50 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. Growth during the historical period was driven by heightened diagnostic recognition, increased incidences of clinical misidentification, greater dependency on invasive biopsy methods, expansion of the population with undiagnosed cases, and a persistent lack of targeted therapeutic options.

The rosai-dorfman disease market size is expected to see strong growth in the next few years. It will grow to $0.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. This future expansion is anticipated to result from broader adoption of molecular diagnostic techniques, elevated awareness surrounding rare diseases, intensified clinical research activity, improved healthcare service availability, increased use of telemedicine platforms, and the ongoing identification of disease-related genetic markers. Notable upcoming trends include the use of artificial intelligence in diagnostic processes, expansion of digital health technologies, collaborative efforts between academic institutions and industry stakeholders, the creation of condition-specific treatment protocols, and the advancement of genomic analysis strategies.

The increasing demand for targeted therapies is expected to drive the growth of the Rosai-Dorfman disease market. Targeted therapies are precision drugs designed to attack specific genetic mutations or cellular mechanisms that promote tumor development, while sparing healthy cells. This demand is growing due to their ability to precisely target disease-causing cells, minimizing damage to healthy tissues, and leading to improved treatment outcomes with fewer side effects than traditional therapies. In the context of Rosai-Dorfman disease, targeted therapies work by blocking critical pathways such as MAPK/ERK that lead to abnormal histiocyte growth, effectively managing the disease with fewer adverse effects. These treatments focus on disease-specific mechanisms, avoiding harm to unaffected tissues. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) reported that there were 247 targeted gene therapies in Phase II in the third quarter of 2023, reflecting a 5% increase compared to the second quarter. As a result, the growing demand for targeted therapies is contributing to the expansion of the Rosai-Dorfman disease market.

The increase in immune-related complications is also anticipated to support the growth of the Rosai-Dorfman disease market. Immune-related complications occur when an overactive or dysfunctional immune system causes harm, often in connection with infections, autoimmune disorders, or immunotherapies. This rise is largely driven by the increased use of immunotherapy, which can lead to an overactive immune response, resulting in inflammation or damage to healthy tissues. Rosai-Dorfman disease is associated with immune system dysregulation, and the growing number of immune-related complications from autoimmune diseases, infections, or immunotherapy side effects is believed to contribute to the onset or exacerbation of the condition. This trend has prompted greater diagnosis, research attention, and therapeutic development. For instance, in November 2024, Versorgungsatlas.de reported that out of 73,241,305 insured individuals in Germany, 6,304,340 were diagnosed with at least one autoimmune disease in 2022, indicating a raw prevalence rate of 8.61%. Therefore, the rising rate of immune-related complications is playing a significant role in advancing the Rosai-Dorfman disease market.

Leading companies in the Rosai-Dorfman disease market are increasingly focused on the development of advanced targeted drugs that inhibit specific molecular pathways responsible for abnormal histiocyte proliferation, aiming to reduce disease severity. Targeted drugs act on particular proteins or genes driving the disease, thereby enhancing treatment precision and minimizing harm to healthy tissues. In October 2022, Memorial Sloan Kettering, a U.S.-based cancer treatment and research center, introduced cobimetinib (Cotellic), a drug approved by the U.S. Food and Drug Administration (FDA). This marked the first approved treatment for adults with Rosai-Dorfman disease and other types of histiocytosis. The therapy represents a major advancement, offering a less toxic, more precise alternative to traditional chemotherapy. It improves patients' quality of life and offers new hope for long-term disease management in individuals affected by these rare blood disorders.

Major players in the rosai-dorfman disease market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche AG, Merck And Co. Inc., Bristol Myers Squibb Company, Novartis AG, Canon Inc., Siemens Healthineers, GE HealthCare, Viatris Inc., Teva Pharmaceutical Industries Ltd., Memorial Sloan Kettering Cancer Center, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Mayo Foundation for Medical Education and Research, Zydus Pharmaceuticals Inc., SternMed GmbH, LGM Pharma, Niksan Pharmaceutical, Herbert Irving Cancer Center.

North America was the largest region in the rosai-dorfman disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rosai-dorfman disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rosai-dorfman disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rosai-dorfman disease market consists of revenues earned by entities by providing services such as diagnostic services, clinical services, therapeutic services, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The rosai-dorfman disease market consists of sales of immunohistochemistry (IHC) kits and reagents, molecular diagnostic kits, targeted therapy drugs, magnetic resonance imaging, and computed tomography scans. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rosai-Dorfman Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rosai-dorfman disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rosai-dorfman disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rosai-dorfman disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Classic (Nodal) Rosai-Dorfman Disease; Extranodal Rosai-Dorfman Disease
• 2) By Procedure Type: Diagnosis; Treatment
• 3) By Route Of Administration: Oral; Parenteral; Sublingual; Nasal
• 4) By Age: Children; Adults
• 5) By End-User: Hospitals; Diagnostics; Cancer Centers; Other End-Users
• Subsegments:
• 1) By Classic (Nodal) Rosai-Dorfman Disease: Cervical Lymph Node Involvement; Axillary Lymph Node Involvement; Inguinal Lymph Node Involvement; Mediastinal Lymph Node Involvement; Generalized Lymphadenopathy
• 2) By Extranodal Rosai-Dorfman Disease: Cutaneous Or Subcutaneous Rosai-Dorfman Disease; Central Nervous System (CNS) Rosai-Dorfman Disease; Orbital Or Ocular Rosai-Dorfman Disease; Bone And Skeletal Rosai-Dorfman Disease; Nasal Or Sinus Rosai-Dorfman Disease; Renal Rosai-Dorfman Disease; Pulmonary Rosai-Dorfman Disease; Hepatic Or Splenic Rosai-Dorfman Disease; Breast Rosai-Dorfman Disease
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; F. Hoffmann-La Roche AG; Merck And Co. Inc.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rosai-Dorfman Disease Market Characteristics

3. Rosai-Dorfman Disease Market Trends And Strategies

4. Rosai-Dorfman Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rosai-Dorfman Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rosai-Dorfman Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rosai-Dorfman Disease Market Growth Rate Analysis
• 5.4. Global Rosai-Dorfman Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rosai-Dorfman Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rosai-Dorfman Disease Total Addressable Market (TAM)

6. Rosai-Dorfman Disease Market Segmentation

• 6.1. Global Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic (Nodal) Rosai-Dorfman Disease
• Extranodal Rosai-Dorfman Disease
• 6.2. Global Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Treatment
• 6.3. Global Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Sublingual
• Nasal
• 6.4. Global Rosai-Dorfman Disease Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adults
• 6.5. Global Rosai-Dorfman Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostics
• Cancer Centers
• Other End-Users
• 6.6. Global Rosai-Dorfman Disease Market, Sub-Segmentation Of Classic (Nodal) Rosai-Dorfman Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Lymph Node Involvement
• Axillary Lymph Node Involvement
• Inguinal Lymph Node Involvement
• Mediastinal Lymph Node Involvement
• Generalized Lymphadenopathy
• 6.7. Global Rosai-Dorfman Disease Market, Sub-Segmentation Of Extranodal Rosai-Dorfman Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous Or Subcutaneous Rosai-Dorfman Disease
• Central Nervous System (CNS) Rosai-Dorfman Disease
• Orbital Or Ocular Rosai-Dorfman Disease
• Bone And Skeletal Rosai-Dorfman Disease
• Nasal Or Sinus Rosai-Dorfman Disease
• Renal Rosai-Dorfman Disease
• Pulmonary Rosai-Dorfman Disease
• Hepatic Or Splenic Rosai-Dorfman Disease
• Breast Rosai-Dorfman Disease

7. Rosai-Dorfman Disease Market Regional And Country Analysis

• 7.1. Global Rosai-Dorfman Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rosai-Dorfman Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rosai-Dorfman Disease Market

• 8.1. Asia-Pacific Rosai-Dorfman Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rosai-Dorfman Disease Market

• 9.1. China Rosai-Dorfman Disease Market Overview
• 9.2. China Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rosai-Dorfman Disease Market

• 10.1. India Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rosai-Dorfman Disease Market

• 11.1. Japan Rosai-Dorfman Disease Market Overview
• 11.2. Japan Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rosai-Dorfman Disease Market

• 12.1. Australia Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rosai-Dorfman Disease Market

• 13.1. Indonesia Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rosai-Dorfman Disease Market

• 14.1. South Korea Rosai-Dorfman Disease Market Overview
• 14.2. South Korea Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rosai-Dorfman Disease Market

• 15.1. Western Europe Rosai-Dorfman Disease Market Overview
• 15.2. Western Europe Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rosai-Dorfman Disease Market

• 16.1. UK Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rosai-Dorfman Disease Market

• 17.1. Germany Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rosai-Dorfman Disease Market

• 18.1. France Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rosai-Dorfman Disease Market

• 19.1. Italy Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rosai-Dorfman Disease Market

• 20.1. Spain Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rosai-Dorfman Disease Market

• 21.1. Eastern Europe Rosai-Dorfman Disease Market Overview
• 21.2. Eastern Europe Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rosai-Dorfman Disease Market

• 22.1. Russia Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rosai-Dorfman Disease Market

• 23.1. North America Rosai-Dorfman Disease Market Overview
• 23.2. North America Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rosai-Dorfman Disease Market

• 24.1. USA Rosai-Dorfman Disease Market Overview
• 24.2. USA Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rosai-Dorfman Disease Market

• 25.1. Canada Rosai-Dorfman Disease Market Overview
• 25.2. Canada Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rosai-Dorfman Disease Market

• 26.1. South America Rosai-Dorfman Disease Market Overview
• 26.2. South America Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rosai-Dorfman Disease Market

• 27.1. Brazil Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rosai-Dorfman Disease Market

• 28.1. Middle East Rosai-Dorfman Disease Market Overview
• 28.2. Middle East Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rosai-Dorfman Disease Market

• 29.1. Africa Rosai-Dorfman Disease Market Overview
• 29.2. Africa Rosai-Dorfman Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rosai-Dorfman Disease Market, Segmentation By Procedure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rosai-Dorfman Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rosai-Dorfman Disease Market Competitive Landscape And Company Profiles

• 30.1. Rosai-Dorfman Disease Market Competitive Landscape
• 30.2. Rosai-Dorfman Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Rosai-Dorfman Disease Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Canon Inc.
• 31.3. Siemens Healthineers
• 31.4. GE HealthCare
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Memorial Sloan Kettering Cancer Center
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Aurobindo Pharma
• 31.10. Mayo Foundation for Medical Education and Research
• 31.11. Zydus Pharmaceuticals Inc.
• 31.12. SternMed GmbH
• 31.13. LGM Pharma
• 31.14. Niksan Pharmaceutical
• 31.15. Herbert Irving Cancer Center

32. Global Rosai-Dorfman Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rosai-Dorfman Disease Market

34. Recent Developments In The Rosai-Dorfman Disease Market

35. Rosai-Dorfman Disease Market High Potential Countries, Segments and Strategies

• 35.1 Rosai-Dorfman Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rosai-Dorfman Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rosai-Dorfman Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer